Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
Authors
Keywords
-
Journal
Lancet Respiratory Medicine
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-06-08
DOI
10.1016/s2213-2600(22)00180-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hospital admission for symptomatic COVID ‐19 and impact of vaccination: analysis of linked data from the Coronavirus Clinical Information Network and the National Immunisation Management Service
- (2022) C. Egan et al. ANAESTHESIA
- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
- (2022) Wanwisa Dejnirattisai et al. CELL
- An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
- (2022) Laura A. VanBlargan et al. NATURE MEDICINE
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
- (2022) Jennifer Hammond et al. NEW ENGLAND JOURNAL OF MEDICINE
- The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
- (2022) Yueh-Ming Loo et al. Science Translational Medicine
- Covid-19: Scientists and medics warn that it is too soon to lift all restrictions in England
- (2022) Matthew Limb BMJ-British Medical Journal
- SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance — Los Angeles County, California, November 7, 2021–January 8, 2022
- (2022) Phoebe Danza et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Waning of COVID-19 vaccine effectiveness: individual and public health risk
- (2022) Vanessa Piechotta et al. LANCET
- Antibody evasion properties of SARS-CoV-2 Omicron sublineages
- (2022) Sho Iketani et al. NATURE
- Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
- (2022) Myron J. Levin et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 evolution during treatment of chronic infection
- (2021) Steven A. Kemp et al. NATURE
- Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients
- (2021) Zelalem G. Dessie et al. BMC INFECTIOUS DISEASES
- Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study
- (2021) Michela Antonelli et al. LANCET INFECTIOUS DISEASES
- Hospitalisation among vaccine breakthrough COVID-19 infections
- (2021) Prerak V Juthani et al. LANCET INFECTIOUS DISEASES
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
- (2021) Michael Dougan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
- (2021) Meagan P. O’Brien et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
- (2021) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
- (2021) Anil Gupta et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
- (2021) Utkarsh Agrawal et al. Lancet Respiratory Medicine
- A minimal common outcome measure set for COVID-19 clinical research
- (2020) John C Marshall et al. LANCET INFECTIOUS DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now